Skip to main content

9 Result(s)

within Seema A. Bhat Remove this filter

and

  1. Article

    Open Access

    Hairy cell leukemia variant and WHO classification correspondence Re: 5th edition WHO classification haematolymphoid tumors: lymphoid neoplasms

    Michael Grever, Leslie Andritsos, Mirela Anghelina, Evgeny Arons… in Leukemia (2024)

    Download PDF (890 KB) View Article

  2. No Access

    Article

    Comparison of karyotype scoring guidelines for evaluating karyotype complexity in chronic lymphocytic leukemia

    Matthew R. Avenarius, Ying Huang, Adam S. Kittai, Seema A. Bhat… in Leukemia (2024)

  3. Article

    Correction: Evaluation of bleeding events in patients receiving acalabrutinib therapy

    Pooja S. Kumar, Tracy Wiczer, Lindsay Rosen, Arthur J. Pollauf, Amy Zheng… in Leukemia (2023)

    Download PDF (220 KB) View Article

  4. No Access

    Article

    Evaluation of bleeding events in patients receiving acalabrutinib therapy

    Pooja S. Kumar, Tracy Wiczer, Lindsay Rosen, Arthur J. Pollauf, Amy Zheng… in Leukemia (2023)

  5. Article

    Open Access

    Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia

    A significant body of literature has been generated related to the detection of measurable residual disease (MRD) at the time of achieving complete remission (CR) in patients with hairy cell leukemia (HCL). Ho...

    Farhad Ravandi, Robert J. Kreitman, Enrico Tiacci, Leslie Andritsos… in Blood Cancer Journal (2022)

    Download PDF (1127 KB) View Article

  6. No Access

    Article

    Depth of response and progression-free survival in chronic lymphocytic leukemia patients treated with ibrutinib

    Audrey M. Sigmund, Ying Huang, Amy S. Ruppert, Kami Maddocks, Kerry A. Rogers… in Leukemia (2022)

  7. Article

    Open Access

    Hypertension and incident cardiovascular events after next-generation BTKi therapy initiation

    Post-market analyses revealed unanticipated links between first-generation Bruton’s tyrosine kinase inhibitor (BTKi) therapy, ibrutinib, and profound early hypertension. Yet, whether this is seen with novel se...

    Sunnia T. Chen, Leylah Azali, Lindsay Rosen… in Journal of Hematology & Oncology (2022)

    Download PDF (1756 KB) View Article

  8. No Access

    Article

    Second cancer incidence in CLL patients receiving BTK inhibitors

    Chronic lymphocytic leukemia (CLL) is associated with perturbed immune function and increased risk for second primary malignancies (SPM). Ibrutinib and acalabrutinib (BTKi) are effective therapies for CLL resu...

    David A. Bond, Ying Huang, James L. Fisher, Amy S. Ruppert, Dwight H. Owen… in Leukemia (2020)

  9. No Access

    Article

    Incidence of opportunistic infections during ibrutinib treatment for B-cell malignancies

    Kerry A. Rogers, Luay Mousa, Qiuhong Zhao, Seema A. Bhat, John C. Byrd… in Leukemia (2019)